199 related articles for article (PubMed ID: 18243703)
1. Conformational significance of EH21A1-A4, phenolic derivatives of geldanamycin, for Hsp90 inhibitory activity.
Onodera H; Kaneko M; Takahashi Y; Uochi Y; Funahashi J; Nakashima T; Soga S; Suzuki M; Ikeda S; Yamashita Y; Rahayu ES; Kanda Y; Ichimura M
Bioorg Med Chem Lett; 2008 Mar; 18(5):1588-91. PubMed ID: 18243703
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of macbecin as an Hsp90 inhibitor.
Martin CJ; Gaisser S; Challis IR; Carletti I; Wilkinson B; Gregory M; Prodromou C; Roe SM; Pearl LH; Boyd SM; Zhang MQ
J Med Chem; 2008 May; 51(9):2853-7. PubMed ID: 18357975
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and anticancer activity of geldanamycin derivatives derived from biosynthetically generated metabolites.
Lee K; Ryu JS; Jin Y; Kim W; Kaur N; Chung SJ; Jeon YJ; Park JT; Bang JS; Lee HS; Kim TY; Lee JJ; Hong YS
Org Biomol Chem; 2008 Jan; 6(2):340-8. PubMed ID: 18175003
[TBL] [Abstract][Full Text] [Related]
4. Potent cytotoxic C-11 modified geldanamycin analogues.
Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y
J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
Onuoha SC; Mukund SR; Coulstock ET; Sengerovà B; Shaw J; McLaughlin SH; Jackson SE
J Mol Biol; 2007 Sep; 372(2):287-97. PubMed ID: 17662999
[TBL] [Abstract][Full Text] [Related]
6. New non-quinone geldanamycin analogs from genetically engineered Streptomyces hygroscopicus.
Wu CZ; Moon AN; Jang JH; Lee D; Kang SY; Park JT; Ahn JS; Hwang BY; Kim YH; Lee HS; Hong YS
J Antibiot (Tokyo); 2011 Jun; 64(6):461-3. PubMed ID: 21448187
[No Abstract] [Full Text] [Related]
7. Engineered biosynthesis of geldanamycin analogs for Hsp90 inhibition.
Patel K; Piagentini M; Rascher A; Tian ZQ; Buchanan GO; Regentin R; Hu Z; Hutchinson CR; McDaniel R
Chem Biol; 2004 Dec; 11(12):1625-33. PubMed ID: 15610846
[TBL] [Abstract][Full Text] [Related]
8. New, non-quinone fluorogeldanamycin derivatives strongly inhibit Hsp90.
Hermane J; Bułyszko I; Eichner S; Sasse F; Collisi W; Poso A; Schax E; Walter JG; Scheper T; Kock K; Herrmann C; Aliuos P; Reuter G; Zeilinger C; Kirschning A
Chembiochem; 2015 Jan; 16(2):302-11. PubMed ID: 25572106
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
[TBL] [Abstract][Full Text] [Related]
10. Macrocyclic lactams as potent Hsp90 inhibitors with excellent tumor exposure and extended biomarker activity.
Zapf CW; Bloom JD; McBean JL; Dushin RG; Nittoli T; Otteng M; Ingalls C; Golas JM; Liu H; Lucas J; Boschelli F; Hu Y; Vogan E; Levin JI
Bioorg Med Chem Lett; 2011 Jun; 21(11):3411-6. PubMed ID: 21515049
[TBL] [Abstract][Full Text] [Related]
11. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
[TBL] [Abstract][Full Text] [Related]
13. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
Chiosis G; Caldas Lopes E; Solit D
Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
[TBL] [Abstract][Full Text] [Related]
15. Geldanamycin and its anti-cancer activities.
Fukuyo Y; Hunt CR; Horikoshi N
Cancer Lett; 2010 Apr; 290(1):24-35. PubMed ID: 19850405
[TBL] [Abstract][Full Text] [Related]
16. The missing C-17 O-methyltransferase in geldanamycin biosynthesis.
Yin M; Lu T; Zhao LX; Chen Y; Huang SX; Lohman JR; Xu LH; Jiang CL; Shen B
Org Lett; 2011 Jul; 13(14):3726-9. PubMed ID: 21682254
[TBL] [Abstract][Full Text] [Related]
17. New, highly active nonbenzoquinone geldanamycin derivatives by using mutasynthesis.
Eichner S; Floss HG; Sasse F; Kirschning A
Chembiochem; 2009 Jul; 10(11):1801-5. PubMed ID: 19554593
[No Abstract] [Full Text] [Related]
18. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel 17-phenylethylaminegeldanamycin derivatives as potent Hsp90 inhibitors.
Li Z; Jia L; Wang J; Wu X; Shi G; Lu C; Shen Y
Chem Biol Drug Des; 2015 Feb; 85(2):181-8. PubMed ID: 24903735
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of heat-shock protein 90 inhibitors: geldanamycin derivatives with broad antiviral activities.
Li YP; Shan GZ; Peng ZG; Zhu JH; Meng S; Zhang T; Gao LY; Tao PZ; Gao RM; Li YH; Jiang JD; Li ZR
Antivir Chem Chemother; 2010 Aug; 20(6):259-68. PubMed ID: 20710066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]